CL2022000496A1 - Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico - Google Patents

Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico

Info

Publication number
CL2022000496A1
CL2022000496A1 CL2022000496A CL2022000496A CL2022000496A1 CL 2022000496 A1 CL2022000496 A1 CL 2022000496A1 CL 2022000496 A CL2022000496 A CL 2022000496A CL 2022000496 A CL2022000496 A CL 2022000496A CL 2022000496 A1 CL2022000496 A1 CL 2022000496A1
Authority
CL
Chile
Prior art keywords
subject
methods
cln2
disease
cln2 disease
Prior art date
Application number
CL2022000496A
Other languages
English (en)
Spanish (es)
Inventor
David Jacoby
Joshua Henshaw
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CL2022000496A1 publication Critical patent/CL2022000496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CL2022000496A 2019-08-29 2022-02-28 Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico CL2022000496A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962893535P 2019-08-29 2019-08-29

Publications (1)

Publication Number Publication Date
CL2022000496A1 true CL2022000496A1 (es) 2022-10-21

Family

ID=72470612

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000496A CL2022000496A1 (es) 2019-08-29 2022-02-28 Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico

Country Status (25)

Country Link
US (1) US20220273775A1 (https=)
EP (2) EP4021575B1 (https=)
JP (2) JP2022546042A (https=)
KR (1) KR20220054375A (https=)
CN (1) CN114828960A (https=)
AR (1) AR119871A1 (https=)
AU (1) AU2020336984B2 (https=)
BR (1) BR112022003598A2 (https=)
CA (1) CA3152521A1 (https=)
CL (1) CL2022000496A1 (https=)
DK (1) DK4021575T3 (https=)
ES (1) ES2987156T3 (https=)
FI (1) FI4021575T3 (https=)
HR (2) HRP20240871T1 (https=)
HU (1) HUE067135T2 (https=)
IL (1) IL290763A (https=)
LT (1) LT4021575T (https=)
MX (1) MX2022002451A (https=)
PL (1) PL4021575T3 (https=)
PT (1) PT4021575T (https=)
RS (1) RS65763B1 (https=)
SI (1) SI4021575T1 (https=)
SM (1) SMT202400315T1 (https=)
TW (1) TW202122106A (https=)
WO (1) WO2021042020A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220323019A1 (en) * 2021-04-02 2022-10-13 Neuropace, Inc. Systems and methods for obtaining a clinical response estimate biomarker using machine-learned models trained on implanted neurostimulator data

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6302685B1 (en) 1997-09-16 2001-10-16 University Of Medicine And Dentistry Of New Jersey Human lysosomal protein and methods of its use
US20020006400A1 (en) * 2000-05-11 2002-01-17 Peter Lobel Recombinant human CLN2 protein and methods of its production and use
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
LT2588130T (lt) * 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
TWI752907B (zh) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 用於治療cln2疾病之tpp1調配物及方法
KR102738860B1 (ko) * 2015-10-23 2024-12-04 유니버시티 오브 아이오와 리써치 파운데이션 리소좀 축적 질환 (lsd)을 갖는 포유동물의 치료 방법에 사용하기 위한 aav 입자를 포함하는 약제학적 조성물
BR112021009370A2 (pt) * 2018-11-14 2021-08-17 Regenxbio Inc. método de tratamento da doença de batten cln2, composição farmacêutica e kit

Also Published As

Publication number Publication date
WO2021042020A1 (en) 2021-03-04
RS65763B1 (sr) 2024-08-30
SI4021575T1 (sl) 2024-10-30
PT4021575T (pt) 2024-07-30
PL4021575T3 (pl) 2024-09-23
EP4438120A3 (en) 2024-12-11
BR112022003598A2 (pt) 2022-05-24
EP4021575B1 (en) 2024-05-22
HRP20220370A1 (hr) 2022-09-16
HRP20240871T1 (hr) 2024-10-11
TW202122106A (zh) 2021-06-16
ES2987156T3 (es) 2024-11-14
EP4438120A2 (en) 2024-10-02
LT4021575T (lt) 2024-08-12
IL290763A (en) 2022-04-01
AU2020336984A1 (en) 2022-03-10
AR119871A1 (es) 2022-01-19
MX2022002451A (es) 2022-06-02
JP2022546042A (ja) 2022-11-02
CA3152521A1 (en) 2021-03-04
FI4021575T3 (fi) 2024-07-24
HUE067135T2 (hu) 2024-10-28
SMT202400315T1 (it) 2024-09-16
DK4021575T3 (da) 2024-08-05
CN114828960A (zh) 2022-07-29
EP4021575A1 (en) 2022-07-06
KR20220054375A (ko) 2022-05-02
JP2025165414A (ja) 2025-11-04
AU2020336984B2 (en) 2026-04-23
US20220273775A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
WO2020047462A3 (en) Methods of treating aging-related disorders
EP4327873A3 (en) Tpp1 formulations and methods for treating cln2 disease
BR112018013151A2 (pt) alfa-glicosidase ácida aumentada para o tratamento da doença de pompe
Jeon et al. Effect of acupuncture on diabetic peripheral neuropathy: an uncontrolled preliminary study from Korea
Blanchard et al. Management of somatic pain induced by head and neck cancer treatment: pain following radiation therapy and chemotherapy. Guidelines of the French Otorhinolaryngology Head and Neck Surgery Society (SFORL)
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
Torzecka et al. The use of isotretinoin in low doses and unconventional treatment regimens in different types of acne: a literature review
MARIANI et al. A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis
CL2022000496A1 (es) Métodos para el tratamiento de la enfermedad cln2 en sujetos pediátrico
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos
Boyaci et al. Comparison of the short-term effectiveness of short-wave diathermy treatment in patients with carpal tunnel syndrome: a randomized controlled trial
WO2020061067A3 (en) Compositions and methods for treating bone injury
Heydari et al. An option for painful diabetic neuropathy with simultaneous ‘antioxidative’and ‘anesthetic’properties: topical citrullus colocynthis
MX2024007354A (es) Metodos de tratamiento usando lou064.
Ediriweera et al. A clinical Study on effect of paste of Haritaki in Padadari (Cracked Feet)
Karahan et al. The effect of paraffin bath therapy versus extracorporeal shockwave therapy in the management of plantar fasciitis: A randomized clinical trial
RU2007120161A (ru) Способ лечения больных остеоартрозом
RU2566201C1 (ru) Способ лечения витилиго
RU2488414C1 (ru) Способ лечения профессионального миофиброза верхних конечностей
RU2743166C2 (ru) Косметический способ
WO2024227085A3 (en) Compounds and methods for treating human subjects
Sabade et al. The clinical study of the efficacy of Viddhagni Karma in the pain management of calcaneal spur
MX2025013084A (es) Compuestos y métodos para tratar sujetos humanos
EA200801278A1 (ru) Способ коррекции функциональных расстройств организма человека
MX2022002947A (es) Avocatina b para el tratamiento de enfermedades y afecciones.